The Long Run with Luke Timmerman podkast

Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With

14.07.2026

The Long Run with Luke Timmerman

0:00

1:08:18

Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.

Więcej odcinków z kanału "The Long Run with Luke Timmerman"

Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets
9 godzin temu
1:36:12
Mathai Mammen, CEO of Cambridge, Mass.-based Parabilis Medicine, on developing alpha helical peptide molecules against hard targets of disease.
Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus
25.08.2026
1:07:17
Gary Nabel, CEO of Weston, Mass.-based ModeX Therapeutics, on developing a vaccine for Epstein-Barr Virus.
Nie przegap odcinka z kanału “The Long Run with Luke Timmerman”! Subskrybuj bezpłatnie w aplikacji GetPodcast.
Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases
11.08.2026
1:17:31
Jason Coloma, CEO of South San Francisco-based Maze Therapeutics, on developing small molecule drugs based on human genetics for kidney diseases.
Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases
28.07.2026
1:07:17
Lyn Baranowski, CEO of Boston-based Avalyn Pharma, on developing inhalable medicines for severe lung diseases.
Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With
14.07.2026
1:08:18
Heather Turner, CEO of New York-based LB Pharma, on developing a new schizophrenia drug designed to better cross the blood-brain barrier, be dosed once daily, and make it easier for patients to take long term.
Ep204: Troy Wilson on Precision Cancer Drugs and Combos
30.06.2026
1:07:27
Troy Wilson, CEO of San Diego-based Kura Oncology, on his career in biotech and developing targeted cancer drugs.
Ep203: Sri Kosuri on Small Molecule Correctors of Disease
16.06.2026
1:11:43
Sri Kosuri, co-founder and CEO of Emeryville, Calif.-based Octant Bio, on small molecules designed to correct protein misfolding and mistrafficking at the root of many diseases.
Ep202: Becky Pferdehirt on Reimagining Science for the AI Era
2.06.2026
1:08:12
Becky Pferdehirt, CEO of Emeryville, CA-based Radial, the life sciences unit of Astera Institute, on reimagining biology to take advantage of advances in AI.
Ep201: Jeremy Levin on Biotech in the Balance
19.05.2026
1:08:40
Jeremy Levin, executive chair of Ovid Therapeutics, discusses his new book "Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust."
Ep200: Richard Pops Reflects on a 35-Year Career in Biotech
5.05.2026
1:13:31
Alkermes CEO Richard Pops reflects on his 35-year career leading the company and its new opportunity in orexin biology for sleep disorders and more neurological conditions.

Więcej odcinków

Odkrywaj najlepsze podcasty dzięki bezpłatnej aplikacji GetPodcast.

Subskrybuj ulubione podcasty, słuchaj odcinków offline i sprawdzaj najlepsze polecane podcasty.

Firma z

Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With

The Long Run with Luke Timmerman

Więcej odcinków z kanału "The Long Run with Luke Timmerman"

Ep209: Mathai Mammen on Developing Drugs Against Undruggable Targets

Ep208: Gary Nabel on Developing a Vaccine for Epstein-Barr Virus

Ep207: Jason Coloma on Genetic Medicines for Kidney Diseases

Ep206: Lyn Baranowski on Inhalable Medicines for Severe Lung Diseases

Ep205: Heather Turner on a Schizophrenia Drug Patients Can Stick With

Ep204: Troy Wilson on Precision Cancer Drugs and Combos

Ep203: Sri Kosuri on Small Molecule Correctors of Disease

Ep202: Becky Pferdehirt on Reimagining Science for the AI Era

Ep201: Jeremy Levin on Biotech in the Balance

Ep200: Richard Pops Reflects on a 35-Year Career in Biotech